Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669558 | 0.89 | GCK (0.52) | GCKCYP2C9KCNH2 | |
| SCHEMBL944632 | 0.87 | GCK (0.46) | GCKCYP2C9KCNH2 | |
| SCHEMBL944890 | 0.87 | GCK (0.46) | GCKCYP2C9KCNH2 | |
| SCHEMBL945737 | 0.87 | GCK (0.46) | GCKCYP2C9KCNH2 | |
| SCHEMBL944628 | 0.84 | GCK (0.51) | GCKCYP2C9KCNH2 | |
| SCHEMBL945339 | 0.84 | GCK (0.45) | GCKKCNH2 | |
| SCHEMBL2658212 | 0.83 | GCK (0.51) | GCKCYP2C9KCNH2 | |
| SCHEMBL946151 | 0.82 | GCK (0.54) | GCKCYP2C9KCNH2 | |
| SCHEMBL946268 | 0.81 | GCK (0.52) | GCKCYP2C9KCNH2 | |
| SCHEMBL945583 | 0.78 | GCK (0.52) | GCKCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | claimed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | GLS, GCKR, HK1 | GCK 4/4885CYP2C9 430/4885KCNH2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.